Cerus (CERS) Expected to Release Quarterly Earnings on Monday

Key Points

• Cerus is expected to report Q3 2026 results after market close on November 2, with analysts forecasting a loss of $0.0125 per share and revenue of $63.25 million.
• In the prior quarter, Cerus reported revenue of $63.30 million and EPS of negative $0.01, meeting earnings expectations while slightly exceeding revenue estimates.
• Shares opened at $2.33, well below the analyst consensus price target of $5.25; ratings are mixed, with three Buy, one Hold, and one Sell recommendation.

Cerus (NASDAQ:CERS - Get Free Report) is projected to release its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.0125) per share and revenue of $63.25 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Cerus (NASDAQ:CERS - Get Free Report) last posted its earnings results on Thursday, July 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative return on equity of 10.19% and a negative net margin of 3.06%. The firm had revenue of $63.30 million for the quarter, compared to analysts' expectations of $62.90 million.

Cerus Price Performance

Shares of NASDAQ CERS opened at $2.33 on Monday. The company has a current ratio of 1.83, a quick ratio of 1.07 and a debt-to-equity ratio of 0.49. Cerus has a 12 month low of $1.38 and a 12 month high of $3.47. The firm has a market capitalization of $469.54 million, a PE ratio of -77.67 and a beta of 1.83. The firm has a fifty day simple moving average of $2.51 and a two-hundred day simple moving average of $2.57.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CERS. Freedom Broker initiated coverage on shares of Cerus in a research note on Thursday, August 20th. They set a "buy" rating and a $6.50 target price on the stock. Wall Street Zen lowered shares of Cerus from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cerus in a report on Monday, September 14th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $5.25.

Insiders Place Their Bets

In related news, insider Chrystal Jensen sold 30,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $2.98, for a total value of $89,400.00. Following the sale, the insider directly owned 936,657 shares of the company's stock, valued at $2,791,237.86. This represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.30% of the stock is currently owned by insiders.

About Cerus

Cerus Corporation is a biomedical products company focused on improving the safety of blood transfusions. Headquartered in Concord, California, the company develops and commercializes technologies designed to reduce the risk of transfusion-transmitted infections and other threats to the blood supply.

Its principal product platform is the INTERCEPT Blood System, which uses pathogen-reduction technology to treat donated blood components. The system is available for platelets and plasma in multiple markets and is designed to inactivate a broad range of viruses, bacteria, parasites and other pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.